TY - JOUR
T1 - Trajectories of functional decline in knee osteoarthritis
T2 - The osteoarthritis initiative
AU - White, Daniel K.
AU - Neogi, Tuhina
AU - Nguyen, Uyen Sa D.T.
AU - Niu, Jingbo
AU - Zhang, Yuqing
N1 - Funding Information:
The OAI is a public-private partnership comprising five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2- 2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health (NIH), a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. Funding for the authors was provided by the Boston Rehabilitation Outcomes Center (Boston ROC) R24HD0065688, ACR/RRF Bridge Funding Award, NIAMS R01AR062506, P60AR047785, NIH U54 GM104941. None of the funders of this manuscript had any role in the design and conduct of this study; collection, management, analysis and interpretation of the data; or preparation of the manuscript.
Publisher Copyright:
© The Author 2015.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Objective. To describe trajectories of functional decline over 84 months and study associated risk factors among adults initially without limitation who had or were at risk of knee OA. Methods. We used annual measures of WOMAC physical function over 84 months from the OA Initiative. We included knees with no functional limitation (i.e. WOMAC= 0) at baseline. Knee-based trajectories of functional decline from WOMAC were identified from a group-based trajectory model (PROC TRAJ). Results. We identified five trajectories from 2110 knees (1055 participants, age 61.0 ± 9.3, BMI 27.1 ± 4.4, 52% women). Half of the knees (54%) remained free of limitation over 84 months, 26% slowly declined to a WOMAC of 1.5, 9% were limitation free for the first 36 months and declined to a WOMAC of 11.3, 6% rapidly declined over the first 12 months and gradually recovered to a WOMAC of 3.3 and 5% steadily declined to a WOMAC of 13.2. Baseline radiographic disease, knee pain, obesity and depressive symptoms at baseline were associated with trajectories of worse functional decline. Conclusion. Five per cent of our sample initially without limitation was on a trajectory of progressive functional decline over 84 months later. We found worse disease and health status at baseline to be associated with faster decline over time.
AB - Objective. To describe trajectories of functional decline over 84 months and study associated risk factors among adults initially without limitation who had or were at risk of knee OA. Methods. We used annual measures of WOMAC physical function over 84 months from the OA Initiative. We included knees with no functional limitation (i.e. WOMAC= 0) at baseline. Knee-based trajectories of functional decline from WOMAC were identified from a group-based trajectory model (PROC TRAJ). Results. We identified five trajectories from 2110 knees (1055 participants, age 61.0 ± 9.3, BMI 27.1 ± 4.4, 52% women). Half of the knees (54%) remained free of limitation over 84 months, 26% slowly declined to a WOMAC of 1.5, 9% were limitation free for the first 36 months and declined to a WOMAC of 11.3, 6% rapidly declined over the first 12 months and gradually recovered to a WOMAC of 3.3 and 5% steadily declined to a WOMAC of 13.2. Baseline radiographic disease, knee pain, obesity and depressive symptoms at baseline were associated with trajectories of worse functional decline. Conclusion. Five per cent of our sample initially without limitation was on a trajectory of progressive functional decline over 84 months later. We found worse disease and health status at baseline to be associated with faster decline over time.
KW - Knee osteoarthritis
KW - Physical function
KW - Trajectory
UR - http://www.scopus.com/inward/record.url?scp=84965058030&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/kev419
DO - 10.1093/rheumatology/kev419
M3 - Article
C2 - 26705330
AN - SCOPUS:84965058030
SN - 1462-0324
VL - 55
SP - 801
EP - 808
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 5
ER -